Sigyn Therapeutics (SIGY) Receivables (2017 - 2020)

Sigyn Therapeutics' (SIGY) quarterly Receivables came in at $756.0 in Q1 2020, down 31.4% quarter-over-quarter from $1102.0 in Q3 2018.

Analysis

Sigyn Therapeutics (SIGY) Receivables (2017 - 2020) Analysis & Trends

Sigyn Therapeutics has disclosed Receivables across 3 years of filings, most recently posting $756.0 for Q1 2020.

In Q1 2020, Receivables changed N/A year-over-year to $756.0; the TTM figure through Mar 2020 stood at $756.0 (changed N/A YoY), while the FY2017 annual figure was $9730.0, changed N/A from the prior year.
Receivables came in at $756.0 for Q1 2020 at Sigyn Therapeutics, down from $1102.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $63002.0 in Q2 2017 to a low of $756.0 in Q1 2020.
Average Receivables over 3 years is $17899.5, with a median of $13526.0 recorded in 2017.
The largest YoY upside for Receivables was 8.01% in 2018 against a maximum downside of 95.22% in 2018.
Over 3 years, Receivables stood at $9730.0 in 2017, then tumbled by 88.67% to $1102.0 in 2018, then slumped by 31.4% to $756.0 in 2020.
Per Business Quant data, the three most recent Receivables figures were $756.0 in Q1 2020, $1102.0 in Q3 2018, and $3013.0 in Q2 2018.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Abbott Laboratories	179.79 Bn	174.18 Bn	7.27 Bn	8.60 Bn
2	Intuitive Surgical	127.69 Bn	122.47 Bn	1.96 Bn	1.67 Bn
3	Medtronic	117.23 Bn	108.41 Bn	6.34 Bn	6.36 Bn
4	Stryker	103.55 Bn	100.07 Bn	4.50 Bn	3.74 Bn
5	Boston Scientific	63.24 Bn	62.70 Bn	3.85 Bn	3.18 Bn
6	Edwards Lifesciences	49.97 Bn	45.72 Bn	1.35 Bn	955.70 Mn
7	Alcon	32.83 Bn	31.37 Bn	1.68 Bn	2.08 Bn
8	Dexcom	32.30 Bn	30.35 Bn	830.00 Mn	1.28 Bn
9	Steris	20.73 Bn	20.25 Bn	684.20 Mn	1.01 Bn
10	Sigyn Therapeutics	48,161.31	-37,409.69	-	-

Historic Data

Download Data